Drug Trial News

RSS

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem, Inc. announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

Study reinforces importance of educating parents and other caregivers of children with food allergy

A team of researchers from Mount Sinai School of Medicine and four other institutions have found that young children with documented or likely allergies to milk and/or eggs, whose families were instructed on how to avoid these and other foods, still experienced allergic reactions at a rate of almost once per year. Of severe cases, less than a third received epinephrine, a medication used to counter anaphylaxis, a life-threatening allergic condition.

25 Jun 2012

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

AbGenomics raises $11 million in current financing round

AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000.

23 Jun 2012

Alexza resubmits ADASUVE NDA to U.S. FDA

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.

22 Jun 2012

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine.

22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.

22 Jun 2012

Study to test NAC and aspirin for people diagnosed with bipolar disorder

A commonly available pharmaceutical drug with anti-inflammatory properties and a nutritional supplement thought to have antioxidant effects are now being tested at The University of Texas Health Science Center at Houston (UTHealth) as add-on therapies for people diagnosed with bipolar disorder.

21 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Omega-3 fatty acid supplements can reduce inflammation in overweight older adults

New research shows that omega-3 fatty acid supplements can lower inflammation in healthy, but overweight, middle-aged and older adults, suggesting that regular use of these supplements could help protect against and treat certain illnesses.

21 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.

19 Jun 2012

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).

19 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

Antiarrhythmic short-term treatment useful for some patients

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.

19 Jun 2012

Drug Trial News

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Study reinforces importance of educating parents and other caregivers of children with food allergy

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

AbGenomics raises $11 million in current financing round

Alexza resubmits ADASUVE NDA to U.S. FDA

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

Study to test NAC and aspirin for people diagnosed with bipolar disorder

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

Omega-3 fatty acid supplements can reduce inflammation in overweight older adults

Furiex initiates MuDelta Phase III studies in IBS-D

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

Gilead's elvitegravir MAA for HIV-1 infection receives EMA validation

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

Antiarrhythmic short-term treatment useful for some patients

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Latest News